ABL Diagnostics has made significant strides in the field of HIV genomics, as evidenced by the recent publication of a peer-reviewed study confirming the efficacy of their DeepChek® Whole Genome HIV-1 Genotyping kit. This groundbreaking assay is recognized as the only full-genome HIV-1 genotyping solution that holds CE-IVD certification on a global scale.
Clinical Validation and Technological Feasibility
The study, published in the Journal of Clinical Virology Plus, highlights the feasibility of implementing whole-genome sequencing using ABL’s technology in routine diagnostic settings. It demonstrates the assay’s ability to provide comprehensive resistance profiling and reliably identify mutations across all genomic regions. This includes minority variants and mutations that extend beyond the classical pol region, which are increasingly relevant for emerging therapeutic classes.
Moreover, the validation underscores the robustness of ABL’s workflow, which is complemented by the DeepChek® HIV Software. This CE-IVD-certified bioinformatics platform is specifically designed to analyze and interpret any CE-IVD HIV-1 sequencing output, regardless of whether it originates from target-specific assays or whole-genome sequencing. By processing raw FASTQ data, the software generates clinically interpretable resistance reports, ensuring consistent interpretations that align with international guidelines.
Market Dynamics and Growth Potential
This validation comes at a pivotal moment for the global HIV genotypic resistance testing market, which is expected to grow from approximately USD 1.34 billion in 2024 to USD 2.51 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 7.2%. The rise in HIV prevalence and the increasing adoption of personalized antiretroviral therapies are key drivers of this growth. Furthermore, international health organizations, including the World Health Organization (WHO), emphasize the necessity of genotypic drug-resistance testing for optimizing antiretroviral therapy, ensuring sustained global demand.
Comprehensive Portfolio Offering
ABL Diagnostics boasts an extensive portfolio of 15 HIV-1 genotyping assays, available in both CE-IVD and research use only (RUO) versions. This includes methodologies based on Sanger sequencing, next-generation sequencing (NGS), and whole-genome workflows. Such a comprehensive offering enables laboratories with varying levels of infrastructure and regulatory requirements to implement high-quality resistance monitoring strategies that are consistent with evolving therapeutic standards.
Financial Performance and Strategic Outlook
From a financial perspective, ABL Diagnostics reported revenues of €2.85 million for the first half of 2025, a slight increase from €2.73 million during the same period in 2024. The growth was primarily driven by the HIV franchise, with DeepChek®HIV products contributing €1.20 million—a remarkable 73% increase year-on-year. The company also achieved a net income of €288 thousand and maintained a positive net cash position of approximately €1.77 million as of June 30, 2025, which positions it well for continued investment in research and development as well as global commercialization efforts.
Navigating Regulatory Landscapes
In light of the increasing regulatory, technical, and automation demands within the market, ABL Diagnostics has strategically aligned its research and development initiatives and regulatory strategies. This positioning enhances its global competitive edge, allowing for sustained innovation and adherence to evolving market standards.
Dr. Sofiane Mohamed, the Head of Research & Development at ABL Diagnostics, emphasized the significance of this peer-reviewed validation. He noted that it reinforces the scientific and clinical strength of their whole-genome HIV-1 assay and highlights the critical role of comprehensive sequencing in the dynamic landscape of HIV therapy. With the CE-IVD DeepChek®HIV Software and a diverse portfolio of 15 assays, ABL offers laboratories a complete and future-proof solution for HIV drug-resistance testing, serving diagnostics, epidemiology, and research needs.
Path Forward for Value Creation
ABL Diagnostics is poised for long-term value creation through its unique combination of CE-IVD certified full-genome technology, advanced analytical software, and a broad product portfolio. The company’s growth trajectory remains contingent on market conditions, regulatory developments, and competitive dynamics as outlined in their public disclosures.
In summary, ABL Diagnostics has solidified its position in the HIV diagnostics landscape with the validation of its innovative whole-genome assay. This achievement not only enhances their product offerings but also aligns with the increasing global demand for precision medicine in HIV treatment.
- Key Takeaways:
- ABL’s DeepChek® Whole Genome HIV-1 Genotyping kit is the only CE-IVD certified full-genome assay globally.
- The global market for HIV genotypic resistance testing is expected to grow significantly by 2033.
- ABL offers a comprehensive range of 15 HIV-1 genotyping assays catering to diverse laboratory needs.
- The company reported a strong financial performance, driven by its HIV product portfolio.
- Strategic alignment in R&D and regulatory approaches strengthens ABL’s market position.
Read more → www.indystar.com